Daniel A. Weiser
<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials. </p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children’s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. – Stony Brook University, NY</li>
<li>Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship – The Children’s Hospital of Philadelphia, PA</li>
</ul>
DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.
<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia. </p><p>Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>
Jacqueline Weingarten-Arams
Nutrition
Pulmonary hypertension
Sepsis
<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams’ pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly’s “Top Doctors: New York Metro Area” for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>
Dawn M. Wahezi
<p>Dr. Wahezi attended medical school at the University of Buffalo, School of Medicine and Biomedical Sciences. She completed her residency training in Pediatrics at The Children’s Hospital at Montefiore, where she stayed on as the inaugural fellow in Pediatric Rheumatology. She subsequently joined the faculty in the Department of Pediatrics at Montefiore and completed a Master’s Degree in clinical research through the Einstein-Montefiore Institute for Clinical and Translational Research Program. Dr. Wahezi is currently an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine and serves as the Program Director of the Pediatric Rheumatology Fellowship Program. </p>
<p>Dr. Wahezi has a special interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis. She has additionally established a pediatric Systemic Lupus Erythematosus (SLE) Cohort and participates in a dedicated, multi-disciplinary pediatric Lupus Nephritis Clinic. Dr. Wahezi is currently engaged in several research projects within the domains of JDM and SLE, contributing to over 40 peer reviewed manuscripts, reviews and scientific abstracts.</p>
<p>Dr. Wahezi is an active member of both the JDM subcommittee and SLE subcommittee within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and has participated in numerous observational and comparative effectiveness research protocols through this research consortium. </p>
<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Pediatric Rheumatology</span>
Dr. Wahezi has a particular research interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis.
<p></p>Dawn Wahezi, MD, MS, is Chief of the Division of Pediatric Rheumatology and Director of the Pediatric Rheumatology Fellowship Program at the Children’s Hospital at Montefiore. She is also Associate Professor of Pediatrics at our Albert Einstein College of Medicine.<br /><br />Dr. Wahezi received her Bachelor of Science from Loyola College and earned her Doctor of Medicine at the State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences. She obtained a Master of Science in Clinical Research at Albert Einstein College of Medicine, and did her residency and fellowship training at CHAM.<br /><br />Dr. Wahezi’s clinical and research interests include juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (SLE). At CHAM, she established an interdisciplinary clinic and comprehensive patient registry for children with JDM and SLE.. Dr. Wahezi is an active member of the American Academy of Pediatrics Rheumatology Advisory Board and the Childhood Arthritis and Rheumatology Research Alliance (CARRA).<p></p>
Rubiahna L. Vaughn
Lisa B. Teh
Ivy Tam
Pediatric Medicine
Dr. Tam’s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children.
<p>Ivy Tam, MD, FAAP, is an Attending Physician and a Non-neonatal Emergency Transport Coordinator at Children’s Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. </p><p>In 2009, Dr. Tam received her Bachelor of Arts in Biological Sciences at Cornell University. She then attended SUNY Upstate Medical University, where she received her Doctor of Medicine in 2013. Dr. Tam began her postgraduate training with a residency in pediatrics at New York University School of Medicine, followed by a fellowship in pediatric hospital medicine in 2018 at the University of California San Diego. </p><p>Dr. Tam’s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children. She has shared her work through presentations in academic forums and scientific meetings, and is currently in the process of being submitted for publication. </p><p>2017, Dr. Tam received the CARES Award from hospital staff at Rady Children’s Hospital for her support during the medical director’s absence. Dr. Tam is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics. </p>
Hina J. Talib
<p>Dr. Hina J. Talib, a Brown University <em>summa cum laude</em> graduate, earned her <em>Bachelor of Science</em> in Neuroscience. She attended medical school at Weill Cornell Medical College, NY where she served as vice-president of her class. She completed her Pediatrics Residency at New York Presbyterian- Weill Cornell and her Chief Residency in Pediatrics at Memorial Sloan Kettering Cancer Center.</p>
<p>Dr. Talib completed a three-year postdoctoral fellowship in Adolescent Medicine in June 2013 at The Children's Hospital at Montefiore. Dr. Talib joined CHAM as Assistant Medical Director for the Michael I. Cohen, MD Adolescent Inpatient Floor where she serves as a teaching hospitalist and chaired the Quality Improvement Committee. In 2015, Dr. Talib was appointed as Associate Director of the Adolescent Medicine Fellowship Training Program. In 2018, Dr. Talib was appointed Medical Director of the Adolescent Inpatient floor. </p>
<p>In addition to providing outpatient sub-specialty care at CHAM, Dr. Talib also cared for youth in foster care at the Children's Aid Society's Bronx Family Health Center. Dr. Talib offers Nexplanon dermal implants, as a method of long acting hormonal contraception, for teen pregnancy prevention at both sites. Her clinical interests include adolescent health, pediatric and adolescent gynecology, contraception, mental health, care of children in foster care, and care of the hospitalized adolescent.</p>
<p>Dr. Talib is board-certified in Pediatrics and in Adolescent Medicine. She is a Fellow of the American Academy of Pediatrics (AAP), and a member of the Society for Adolescent Health and Medicine (SAHM) and the North American Society for Pediatric and Adolescent Gynecology (NASPAG). She serves as Associate Editor of the <em>Journal of Pediatric and Adolescent Gynecology</em>, the official journal of NASPAG, and as a co-chair of the NASPAG resident education committee. In addition, Dr. Talib is a recent past President of the Executive Board of the New York chapter of SAHM.</p>
<p>Dr Talib currently provies pediatric and adolescent medicine care at the Atria Institute. </p>
<p>Connect with Dr. Talib at her website drhinatalib.com or follow Dr. Talib at her instagram @teenhealthdoc. </p>
Dr. Talib's clinical focus is adolescent health, pediatrics and adolescent gynecology, contraception, mental health, care of children in foster care and care of hospitalized adolescents.
Dr. Talib has been studying the effects of Vitamin D deficiency in the adolescent age group since 2012. In 2013, she published a study on influences of partner and relationship factors in HIV testing in Bronx youth. Through her work on the CHAM HIV Testing Task Force, she is currently conducting a quality improvement intervention to increase HIV testing in hospitalized adolescents.
<p><strong>Talib HJ,</strong> Coupey SM. Excessive Uterine Bleeding. <em>Adolesc Med</em> 2012; 23:53-72</p>
<p><strong>Talib HJ</strong>, Alderman EM.Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications. <em>J Pediatr Adolesc Gynecol </em>2013; 26(1):7-15</p>
<p><strong>Talib HJ,</strong> Silver EJ, Coupey SM, Bauman LJ. The influence of individual, partner, and relationship factors in HIV testing in adolescents. <em>AIDS Patient Care STDs</em> 2013; 27(11): 637-4</p>
<p><strong>Talib HJ</strong>, Ponnapakkam T, Gensure R, Cohen HW, Coupey SM. Treatment of vitamin D deficiency in predominantly Hispanic and black adolescents: a randomized clinical trial. <em>J Pediatr</em> 2016; 170:266-72. PMID: 26707619</p>
<p><strong>Talib HJ</strong><span style="text-decoration: underline;">,</span> Silver EJ, Alderman EM. Challenges to adolescent confidentiality in a children’s hospital. <em>Hosp Pediatr</em> 2016; 6(8):490-5. PMID: 27461762</p>
<p>Fleming N, Aimes-Oeschlager A, Browner-Elhanan KJ, Kaul P, <strong>Talib HJ</strong>, Wheeler C, Loveless M. Resident Education Curriculum in Pediatric and Adolescent Gynecology: The Short Curriculum. <em>J Pediatr Adolesc Gynecol </em>2014; 27(2):117-20</p>
<p><strong>Talib HJ</strong>, Karjane N, Teelin K, Abraham M, Holt S, Chelvakumar G, Dumont T, Huguelet PS, Connor L, Wheeler C, Fleming N. Resident education curriculum in pediatric and adolescent gynecology: the short curriculum 2.0. <em>J Pediatr Adolesc Gynecol</em> 2018; 31(2):71-76</p>
<p>Bhalakia AM, <strong>Talib HJ</strong>, Choi J, Watnick D, Bochner R, Futterman D, Gross E. Acceptance of routine HIV testing by hospitalized adolescents and young adults. <em>Hospital Pediatr</em> 2018; 8(4):187-193. PMID:29599198</p>
<p>Hina J. Talib, MD, is Director of the Adolescent Medicine Fellowship Program and an Attending Physician in the Division of Adolescent Medicine at Children’s Hospital at Montefiore. Dr. Talib is also an Associate Professor of Pediatrics at our Albert Einstein College of Medicine. Her clinical focus is adolescent health, pediatrics and adolescent gynecology, contraception, mental health, care of children in foster care and care of hospitalized adolescents. She joined the Montefiore team in 2013.</p><p>Dr. Talib received her Bachelor of Science in Neuroscience in 2001 from Brown University. In 2006, she received her Doctor of Medicine from Weill Cornell Medical College of Cornell University. In 2009, Dr. Talib completed a residency in pediatrics at New York Presbyterian Phyllis and David Komansky Center for Children’s Health – Weill Cornell Medical Center. She became Chief Resident in Pediatrics at Memorial Sloan Kettering Cancer Center that same year. Dr. Talib went on to complete a postdoctoral fellowship in Adolescent Medicine at CHAM in 2013.</p><p>Dr. Talib has been studying the effects of Vitamin D deficiency in the adolescent age group since 2012. In 2013, she published a study on influences of partner and relationship factors in HIV testing in Bronx youth. Through her work on the CHAM HIV Testing Task Force, she is currently conducting a quality improvement intervention to increase HIV testing in hospitalized adolescents. Her work has been published numerous times in peer reviewed journals, review articles, and books and has been presented at national meetings.</p><p>In 2014, Dr. Talib won Best Platform Presentation for her work, “Randomized Clinical Trial of Two High-dose vs. Low-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents Living in a Northeast City” at Pediatric Research Day at CHAM.</p><p>Dr. Talib is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics, Section in Adolescent Health.</p>
Michael L. Swerdlow
<p>Dr. Michael Swerdlow graduated from The University Of Pennsylvania School of Medicine. He did a medical residency at Mt. Sinai Hospital in New York. He then completed the neurology residency at Albert Einstein College of Medicine in The Bronx. He then did a fellowship Neuromuscular diseases at the N.I.H. in Bethesda. He joined the faculty at Montefiore Hospital and Albert Einstein College. He presently is a Professor of Clinical Neurology. He has a large faculty practice with Dr. David Kaufman as "K and S." He teaches residents and supervises the Neurology Clinic and is involved in CME teaching. Special areas of interest include muscle disorders, Myasthenia Gravis, Multiple Sclerosis and disorders of the spine.</p>